The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...
Hosted on MSN1mon
Onconetix settles with IQVIA, adjusts accounts payableOnconetix, Inc. (NASDAQ:ONCO), a pharmaceutical company with a market capitalization of $4.48 million, has reached a settlement agreement with IQVIA, Inc., a provider of advanced analytics ...
Cincinnati, OH, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) (the “Company”) announced that it received a letter from The Nasdaq Capital Market (“Nasdaq”) on December 6 ...
Hosted on MSN10mon
ONCO Stock Earnings: Onconetix Reported Results for Q1 2024Onconetix (NASDAQ:ONCO) just reported results for the first quarter of 2024. Onconetix reported earnings per share of -50 cents. The company reported revenue of $700,433. InvestorPlace Earnings is ...
06:17 EST Onconetix (ONCO) files to sell 50M shares of common stock for holders Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now ...
Onconetix, Inc., a pharmaceutical preparations company with a market capitalization of $4.48 million, has entered into a material definitive agreement and created a direct financial obligation, ...
Short interest in Onconetix Inc (NASDAQ:ONCO) decreased during the last reporting period, falling from 1.33M to 193.86K. This put 1.78% of the company's publicly available shares short.
Nasdaq provides visual representation of analyst expected earnings growth. Read our earnings report guide before you consider the forecast information when making investment decisions. Visit the ...
Onconetix, Inc. is a commercial stage biotechnology company, which engages in the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians ...
Cincinnati, OH, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) (the “Company”) announced that it received a letter from The Nasdaq Capital Market (“Nasdaq”) on December 6, 2024 ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results